Autologous Platelet Rich Plasma Combined to Hyaluronic Acid Obtained With Regen-Kit BCT-HA in Aesthetic Medicine

Efficacy of the Use of Autologous Platelet Rich Plasma Combined to Hyaluronic Acid Obtained With regenKit BCT-HA Cellular Matrix for Skin in Aesthetic Medicine

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02832583

Enrollment

Registered

2016-07-14

Start date

2014-12-31

Completion date

2016-06-30

Last updated

2016-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Wrinkling

Keywords

PRP, hyaluronic acid, mesotherapy, skin wrinkle, skin rejuvenation

Brief summary

The aim of this prospective study is to assess the efficacy of autologous Platelet Rich Plasma combined with Hyaluronic Acid prepared with RegenKit-BCT HA Cellular Matrix on skin rejuvenation. Thirty-one patients were included and received three PRP-AH injection sessions 4 weeks apart into the cheeks. The outcomes were assessed at baseline, 1, 3 and 6 months after the last injection session. Safety was assessed by reported adverse event analysis.

Interventions

DEVICERegenkit BCT-HA Cellular Matrix

To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged over 40 years with chronological aging * Completed informed consent form

Exclusion criteria

* Pregnancy or breastfeeding * Patients younger than 40 years * Use of product or treatment aimed to improve skin rejuvenation over the last six months before study start, * patients with known hypersensitivity to HA, * patients with eczema flare-up, * patients with active skin disorder infection including herpes virus infection, active hepatitis or human infection virus infection. * Dermatological diseases affecting the face * Auto-immune disease such as Hashimoto, rheumatoid arthritis. * Malignancy with or without metastatic disease * Chemotherapy * Anticoagulant therapy

Design outcomes

Primary

Measure	Time frame	Description
Evaluate the changes of facial apparent overall assessed by FACE-Q scale.	6 months	Evaluate changes in facial apparent assessed by FACE-Q scale after 6 month of Autologous Platelet Rich Plasma combined to hyaluronic acid compared to baseline (before treatment)

Secondary

Measure	Time frame	Description
Evaluate the changes of skin elasticity assessed by the Cutometer®	6 months	Evaluate changes in skin elasticity assessed by the Cutometer® after 6 months of Autologous Platelet Rich Plasma combined to hyaluronic acid compared to baseline (before treatment).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026